Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Natural Killer Cell Immunotherapy in Combination With PARP-inhibition to Overcome NKG2D Mediated Immune Evasion in Acute Myeloid Leukemia

NCT05319249 is registered in ClinicalTrials.gov with German Cancer Research Center as lead sponsor.

NCT NCT05319249
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05319249 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Natural Killer Cell Immunotherapy in Combination With PARP-inhibition to Overcome NKG2D Mediated Immune Evasion in Acute Myeloid Leukemia
Lead sponsor
German Cancer Research Center
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
June 30, 2024
Completion date
June 30, 2028
Enrollment
54 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia